Impact of Life Expectancy and Tumor Doubling Time on the Clinical Significance of Prostate Cancer in Japan

Japanese Journal of Clinical Oncology

Volumn 27, Issue 6, 1997, Pages 394-400

  Egawa, Shin ^a   Matsumoto, Kazumasa ^a   Iwamura, Masatsugu ^a   Uchida, Toyoaki ^a   Kuwao, Sadahito ^a   Koshiba, Ken ^a  

^a KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Clinical significance; Life expectancy; Prostate cancer; Radical prostatectomy; Tumor doubling time

Indexed keywords

AGED; ARTICLE; CELL DIVISION; HUMAN; JAPAN; LIFE EXPECTANCY; MALE; MIDDLE AGED; MORTALITY; OUTCOME ASSESSMENT; PATHOLOGY; PROSTATE TUMOR; PROSTATECTOMY; SURVIVAL RATE;

AGED; AGED, 80 AND OVER; CELL DIVISION; HUMANS; JAPAN; LIFE EXPECTANCY; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); PROSTATECTOMY; PROSTATIC NEOPLASMS; SURVIVAL RATE;

EID: 0031304163     PISSN: 03682811     EISSN: None     Source Type: Journal    
DOI: 10.1093/jjco/27.6.394     Document Type: Article

References (29)

1. Kakizoe T. Figures on Cancer in Japan - 1995. Tokyo: Foundation for Promotion of Cancer Research, 1995:34-5 (in Japanese).
2. Tominaga S, Aoki K, Hanai A, Kurihara N. Cancer Statistics - Incidence/ Mortality/Prognosis, 1993. Tokyo: Shinohara, 1993,154-70 (in Japanese).
3. Statistics and Information Department. Vital Statistics 1995 Japan, vol. 3. Tokyo: Minister's Secretariat, Ministry of Health and Welfare, 1995:100-1 (in Japanese).
4. Potosky AL, Miller BA, Albertsen PC, Kramer BS. The role of increasing detection in the rising incidence of prostate cancer. JAMA 1995;273:548-52.
5. Egawa S, Suyama K, Ohori M, Kawakami T, Kuwao S, Hirokado K, Hirano S, Yokoyama E, Uchida T, Koshiba K. Early detection of prostate cancer. Results of a prostate specific antigen-based detection program in Japan. Cancer 1995;76:463-72.
6. Lu-Yao GL, McLerran D, Watson J, Wennberg JE. An assessment of radical prostatectomy. Time trends, geographic variation and outcomes. JAMA 1993;269:2633-6.
7. Fleming C, Wasson JH, Albertsen PC, Barry MJ, Wennberg JE. A decision analysis of alternative treatment strategies for clinically localized prostate cancer. JAMA 1993;269:2650-8.
8. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J The impact of comorbidity on life expectancy among men with localized prostate cancer. J Urol 1996;156:127-32.
9. Dugan JA, Bostwick DG, Myers RP, Qian J, Bergstralh EJ, Oesterling JE. The definition and preoperative prediction of clinically insignificant prostate cancer. JAMA 1996;275:288-94.
10. Gronberg H, Damber J-E, Jonsson H, Lenner P Patient age as a prognostic factor in prostate cancer. J Urol 1994;152:892-5.
11. International Union Against Cancer TNM Atlas, 3rd ed, 2nd revision. New York: Springer, 1992;241-50.
12. Walsh PC Radical retropubic prostatectomy: an anatomic approach. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED, editors. Campbell's Urology, vol. 3, 6th ed. Philadelphia: WB Saunders, 1992;2865-86.
13. Machida T, Ohishi Y, Wada T, Akimoto S, Shimazaki J, Oda H, et al. Clinical evaluation of new kit (IMx PA Dainapack) for detection of serum prostate specific antigen. Acta Urol Jpn 1993;39:977-84.
14. Statistics and Information Department. The 17th Life Tables. Tokyo: Minister's Secretariat, Ministry of Health and Welfare, 1992;94-7.
15. D'Amico AV, Hanks GE. Linear regressive analysis using prostate-specific antigen doubling time for predicting tumor biology and clinical outcome in prostate cancer. Cancer 1993;72:2638-43.
16. Schmid H, McNeal JE, Stamey TA. Observations on the doubling time of prostate cancer: the use of serial prostate-specific antigen in patients with untreated disease as a measure of increasing cancer volume. J Urol Cancer 1993;71:2031-40.
17. Ohori M, Wheeler TM, Dunn JK, Stamey TA, Scardino PT. The pathological features and prognosis of prostate cancer detectable with current diagnostic tests. J Urol 1994;152:1714-20.
18. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathologic and clinical findings to predict tumor extent of nonpalpable (stageT1c) prostate cancer. JAMA 1994;271:368-74.
19. Stamey TA, McNeal JE. Adenocarcinoma of the prostate. In: Walsh PC, Retik AB, Stamey TA, Vaughan ED, editors. Campbell's Urology, vol. 3, 6th ed. Philadelphia: WB Saunders, 1992;1159-221.
20. Humphrey PA, Keetch DW, Smith DS, Shepherd DL, Catalona WJ. Prospective characterization of pathological features of prostatic carcinomas detected via serum prostate specific antigen based screening. J Urol 1996;155-816-20.
21. Woolf SH. Defining clinically insignificant prostate cancer. JAMA 1996;276:28-9.
22. Egawa S, Satoh T, Suyama K, Uchida T, Koshiba K. Risk of progression and dying of clinically localized prostate cancer in Japan. World J Urol 1996;14:363-8.
23. Friedman AC, Radecki PD, Shea FJ, Stein BS Prostate-neoplastic disorders. In: Petersen RO, editor. Urologic Pathology Philadelphia: JB Lippincott, 1986, 613-67.
24. Carter HB, Piantadosi S, Isaacs JT. Clinical evidence for and implications of the multistep development of prostate cancer. J Urol 1990;143:742-6.
25. Hutchison GB. Incidence and etiology of prostate cancer. Urol 1981;17(Suppl. 3):4-10.
26. Oesterling JE, Suman VJ, Zincke H, Bostwick DG. PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors. Urol Clin North Am 1993;4:687-93.
27. Blute ML, Nativ O, Zincke H, Farrow GM, Themeau T, Lieber MM. Pattern of failure after radical retropubic prostatectomy for clinically and pathologically localized adenocarcinoma of the prostate: influence of tumor deoxyribonucleic acid ploidy. J Urol 1989;142:1262-5.
28. Fowler JF Jr, Terrell FL, Renfroe DL Co-morbidities and survival of men with localized prostate cancer treated with surgery or radiation therapy. J Urol 1996;156:1714-8.
29. Albertsen PC, Fryback DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer JAMA 1995;274:626-31.